- Home
- ORKA vs AVDL Comparison
ORKA vs AVDL Comparison
Compare ORKA & AVDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORKA
- AVDL
- Stock Information
- Founded
- ORKA 2004
- AVDL 2015
- Country
- ORKA United States
- AVDL Ireland
- Employees
- ORKA N/A
- AVDL N/A
- Industry
- ORKA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- AVDL Biotechnology: Pharmaceutical Preparations
- Sector
- ORKA Health Care
- AVDL Health Care
- Exchange
- ORKA Nasdaq
- AVDL Nasdaq
- Market Cap
- ORKA 1.0B
- AVDL 867.3M
- IPO Year
- ORKA N/A
- AVDL 1996
- Fundamental
- Price
- ORKA $11.02
- AVDL $8.41
- Analyst Decision
- ORKA Strong Buy
- AVDL Strong Buy
- Analyst Count
- ORKA 7
- AVDL 7
- Target Price
- ORKA $39.67
- AVDL $18.86
- AVG Volume (30 Days)
- ORKA 263.4K
- AVDL 1.3M
- Earning Date
- ORKA 03-04-2025
- AVDL 03-03-2025
- Dividend Yield
- ORKA N/A
- AVDL N/A
- EPS Growth
- ORKA N/A
- AVDL N/A
- EPS
- ORKA N/A
- AVDL N/A
- Revenue
- ORKA N/A
- AVDL $138,160,000.00
- Revenue This Year
- ORKA N/A
- AVDL $515.49
- Revenue Next Year
- ORKA N/A
- AVDL $48.85
- P/E Ratio
- ORKA N/A
- AVDL N/A
- Revenue Growth
- ORKA N/A
- AVDL 1523.50
- 52 Week Low
- ORKA $10.61
- AVDL $7.39
- 52 Week High
- ORKA $53.88
- AVDL $19.09
- Technical
- Relative Strength Index (RSI)
- ORKA N/A
- AVDL 45.85
- Support Level
- ORKA N/A
- AVDL $8.27
- Resistance Level
- ORKA N/A
- AVDL $9.34
- Average True Range (ATR)
- ORKA 0.00
- AVDL 0.44
- MACD
- ORKA 0.00
- AVDL 0.09
- Stochastic Oscillator
- ORKA 0.00
- AVDL 43.29
About ORKA Oruka Therapeutics Inc. Common Stock
Oruka Therapeutics Inc is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. It is to offer patients suffering from chronic skin diseases like plaque psoriasis.
About AVDL Avadel Pharmaceuticals plc
Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. It identifies, develops, and commercializes branded pharmaceutical products including controlled-release therapeutic products based on its proprietary drug delivery technologies in the United States. The company is engaged in development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy.